Lampalizumab Biosimilar - Research Grade

Human

CFD

>1mg/ml

Fab - G1 - kappa

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

P00746

1675

Blue ice

This is an unconjugated, non-therapeutic recombinant analog of lampalizumab, provided for research use only. Lampalizumab is an antigen-binding fragment (Fab) directed against complement factor D (CFD, UniProt P00746), the rate-limiting protease of the alternative complement pathway. The molecule was originally developed as a candidate for geographic atrophy in age-related macular degeneration, and the antibody sequence remains a widely referenced tool for interrogating alternative-pathway biology. This research-grade preparation is built around the CFD target and is supplied as a Fab (human IgG1/kappa framework), making it useful as a positive control in complement assays, for benchmarking anti-factor D reagents, for in-vitro neutralisation and binding studies, and for preclinical method development. It is offered as a low-endotoxin, bulk (mg-g) format suitable for larger in-vitro and preclinical workflows. It is not the clinical drug and is not intended for human or veterinary use. As a Fab fragment it lacks an Fc region, so effector functions such as ADCC and complement fixation by the reagent itself do not apply. Complement factor D (CFD, adipsin; UniProt P00746) is a small serine protease that is the rate-limiting enzyme of the alternative complement pathway. It circulates largely in its mature, active form and acts on a single physiological substrate: factor B when the latter is bound to C3b within the pro-convertase complex (C3bB). By cleaving factor B into Ba and Bb, factor D generates the alternative-pathway C3 convertase (C3bBb), driving amplification of complement activation and downstream opsonisation, inflammation, and membrane-attack-complex formation. Because factor D is present at low concentration and is rate-limiting, it is an attractive point for pharmacological inhibition of the alternative pathway. CFD is also expressed by adipocytes, linking complement to metabolic signalling. Dysregulated alternative-pathway activity is implicated in age-related macular degeneration, paroxysmal nocturnal haemoglobinuria, and other complement-mediated conditions.

Adipsin, C3 convertase activator, Properdin factor D, Complement factor D, DF, PFD

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Lampalizumab (anti-CFD) Biosimilar

Q: Is the Lampalizumab biosimilar available in bulk mg to gram quantities?

A: Yes — it is manufactured in scalable milligram to gram quantities for high-throughput and bulk in vivo experiments.

Q: Is this research-grade Lampalizumab biosimilar suitable for in vivo use?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Lampalizumab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Lampalizumab that binds CFD; for research use only.